CLINICAL_TRIALS
trial_result
· 2026-03-12
Clinical Trial Update: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome [Phase 2, Phase 3]
Summary
A Boehringer Ingelheim trial evaluating Spesolimab for Netherton Syndrome in Phase 2/Phase 3 has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Netherton Syndrome | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2026-03-12